Meeting
2020 ASCO Virtual Scientific Program
Development and validation of the PREMMplus clinical prediction model for multigene hereditary cancer risk assessment.
Authors
Matthew B. Yurgelun
Dana-Farber Cancer Institute, Boston, MA
Matthew B. Yurgelun , Hajime Uno , C. Sloane Furniss , Chinedu I. Ukaegbu , Miki Horiguchi , Anu B. Chittenden , Tara Fehlmann , Amal Yussuf , Holly LaDuca , Judy Ellen Garber , Sapna Syngal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Cancer Prevention, Risk Reduction, and Genetics
Track
Prevention, Risk Reduction, and Genetics
Sub Track
Germline Genetic Testing
Citation
J Clin Oncol 38: 2020 (suppl; abstr 1579)
DOI
10.1200/JCO.2020.38.15_suppl.1579
Abstract #
1579
Poster Bd #
71
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Safety of multiplex gene testing for inherited cancer risk in a fully accrued prospective trial.
First Author: Allison W. Kurian
Poster
2017 ASCO Annual Meeting
Expanded yield of multiplex panel testing in fully accrued prospective trial.
First Author: Gregory Idos
Poster
2019 ASCO Annual Meeting
Prevalence and penetrance of breast cancer-associated mutations identified by multiple-gene sequencing in the Women’s Health Initiative.
First Author: Allison W. Kurian
Poster
2017 ASCO Annual Meeting
Performance of mutation risk prediction models in a racially diverse multi-gene panel testing cohort.
First Author: Gregory Idos